CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Production of functional CD19 CAR T cells under hypoxic manufacturing conditions.
Production of functional CD19 CAR T cells under hypoxic manufacturing conditions.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
我们证明,在 2% O₂条件下生产并无不利影响,反而赋予 CAR-T 细胞细微但持久的功能和表型变化,这值得进一步研究低氧生产对低氧肿瘤微环境中 CAR-T 细胞功能性的影响。
研究者对来自健康供者或CLL患者、分别在21%氧气(常氧CAR)或2%氧气(低氧CAR)条件下生产的CD19靶向CAR-T 细胞,进行了体外表型和功能评估。
在2%氧气下生产健康供者来源CAR-T 细胞,促进了幼稚样亚群富集。低氧CAR与常氧CAR细胞功能不同:低氧CAR的CD4+细胞较常氧CAR的CD4+细胞产生更多IL-2和肿瘤坏死因子。2%氧气下生产并未损害细胞存活或受到相应抗原刺激后的增殖,且增强了细胞活化。经低氧环境长期刺激后,低氧CAR产品仍富含幼稚样细胞,并保留细胞毒性和细胞因子产生能力。对于CLL患者来源CAR-T 细胞,常氧CAR与低氧CAR亚群的功能和表型相近,但线粒体代谢不同。讨论:研究显示,在2%氧气下生产CAR-T 细胞并无不利影响,反而会带来细微但持久的功能和表型改变,值得进一步研究低氧条件生产对CAR-T 细胞在缺氧肿瘤微环境中功能的影响。
We performed in vitro phenotypic and functional assessments of CD19-directed CAR T cells produced in either 21% ( Nor CAR) or 2% ( Hyp CAR) O 2 derived from healthy donors (HDs) or patients with CLL.
Production of HD-derived CAR T cells in 2% O 2 promoted the enrichment of a na ve-like subset. Hyp CAR and Nor CAR cells were functionally distinct; CD4+ Hyp CAR cells produced more IL-2 and tumor necrosis factor than CD4+ Nor CAR cells. Production in 2% O 2 was not detrimental to viability or proliferation upon cognate antigen-stimulation and led to increased activation. After chronic stimulation in hypoxia, Hyp CAR-product remained enriched in na ve-like cells, and demonstrated cytotoxic and cytokine production capacity. In CAR T cells derived from patients with CLL, Nor CAR and Hyp CAR subsets were functionally and phenotypically comparable, but displayed different mitochondrial metabolism. DISCUSSION: We demonstrated that production in 2% O 2 is not detrimental, confers subtle but lasting functional and phenotypic changes in CAR T cells warranting further research on the impact of hypoxic production on CAR T cell functionality in hypoxic tumor microenvironments.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。